148 related articles for article (PubMed ID: 14726395)
1. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia.
Kindler T; Breitenbuecher F; Marx A; Beck J; Hess G; Weinkauf B; Duyster J; Peschel C; Kirkpatrick CJ; Theobald M; Gschaidmeier H; Huber C; Fischer T
Blood; 2004 May; 103(10):3644-54. PubMed ID: 14726395
[TBL] [Abstract][Full Text] [Related]
2. Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
Kindler T; Breitenbuecher F; Marx A; Hess G; Gschaidmeier H; Gamm H; Kirkpatrick CJ; Huber C; Fischer T
Blood; 2003 Apr; 101(8):2960-2. PubMed ID: 12480706
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response.
Brandwein JM; Hedley DW; Chow S; Schimmer AD; Yee KW; Schuh AC; Gupta V; Xu W; Kamel-Reid S; Minden MD
Leukemia; 2011 Jun; 25(6):945-52. PubMed ID: 21403650
[TBL] [Abstract][Full Text] [Related]
5. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
Ottmann OG; Druker BJ; Sawyers CL; Goldman JM; Reiffers J; Silver RT; Tura S; Fischer T; Deininger MW; Schiffer CA; Baccarani M; Gratwohl A; Hochhaus A; Hoelzer D; Fernandes-Reese S; Gathmann I; Capdeville R; O'Brien SG
Blood; 2002 Sep; 100(6):1965-71. PubMed ID: 12200353
[TBL] [Abstract][Full Text] [Related]
6. Complete remission of third recurrence of acute myeloid leukemia after treatment with imatinib (STI-571).
Schittenhelm M; Aichele O; Kröber SM; Brümmendorf T; Kanz L; Denzlinger C
Leuk Lymphoma; 2003 Jul; 44(7):1251-3. PubMed ID: 12916883
[TBL] [Abstract][Full Text] [Related]
7. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
Sugiura H; Fujiwara Y; Ando M; Kawai A; Ogose A; Ozaki T; Yokoyama R; Hiruma T; Ishii T; Morioka H; Mugishima H
J Orthop Sci; 2010 Sep; 15(5):654-60. PubMed ID: 20953927
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?
Malagola M; Martinelli G; Rondoni M; Paolini S; Gaitani S; Arpinati M; Piccaluga PP; Amabile M; Basi C; Ottaviani E; Candoni A; Gottardi E; Cilloni D; Bocchia M; Saglio G; Lauria F; Fanin R; Visani G; Marrè MC; Maderna M; Rancati F; Vinaccia V; Russo D; Baccarani M
Blood; 2005 Jan; 105(2):904; author reply 905. PubMed ID: 15632213
[No Abstract] [Full Text] [Related]
9. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.
Schneider BJ; Kalemkerian GP; Ramnath N; Kraut MJ; Wozniak AJ; Worden FP; Ruckdeschel JC; Zhang X; Chen W; Gadgeel SM
Clin Lung Cancer; 2010 Jul; 11(4):223-7. PubMed ID: 20630823
[TBL] [Abstract][Full Text] [Related]
10. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
12. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
[TBL] [Abstract][Full Text] [Related]
13. Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).
Scheuring UJ; Pfeifer H; Wassmann B; Bruck P; Atta J; Petershofen EK; Gehrke B; Gschaidmeier H; Hoelzer D; Ottmann OG
Blood; 2003 Jan; 101(1):85-90. PubMed ID: 12393581
[TBL] [Abstract][Full Text] [Related]
14. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin.
Corbacioglu S; Kilic M; Westhoff MA; Reinhardt D; Fulda S; Debatin KM
Blood; 2006 Nov; 108(10):3504-13. PubMed ID: 16840725
[TBL] [Abstract][Full Text] [Related]
15. Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response.
Iurlo A; Gianelli U; Beghini A; Spinelli O; Orofino N; Lazzaroni F; Cambiaghi S; Intermesoli T; Rambaldi A; Cortelezzi A
Oncotarget; 2014 Jul; 5(13):4665-70. PubMed ID: 25015329
[TBL] [Abstract][Full Text] [Related]
16. Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.
Faderl S; Pal A; Bornmann W; Albitar M; Maxwell D; Van Q; Peng Z; Harris D; Liu Z; Hazan-Halevy I; Kantarjian HM; Estrov Z
Cancer Res; 2009 May; 69(9):3910-7. PubMed ID: 19383925
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.
Mirza AS; Lancet JE; Sweet K; Padron E; Pinilla-Ibarz J; Nardelli L; Cubitt C; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):902-907. PubMed ID: 29030092
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
19. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
Growney JD; Clark JJ; Adelsperger J; Stone R; Fabbro D; Griffin JD; Gilliland DG
Blood; 2005 Jul; 106(2):721-4. PubMed ID: 15790786
[TBL] [Abstract][Full Text] [Related]
20. Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).
Wassmann B; Pfeifer H; Scheuring U; Klein SA; Gökbuget N; Binckebanck A; Martin H; Gschaidmeier H; Hoelzer D; Ottmann OG
Leukemia; 2002 Dec; 16(12):2358-65. PubMed ID: 12454740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]